Gilead Sciences, Inc. is a Delaware-incorporated biopharmaceutical company headquartered in Foster City, California, whose marketed products include HIV therapies (BIKTARVY, DESCOVY, SUNLENCA), oncology cell therapies (YESCARTA, TECARTUS), hepatitis treatments, and other antiviral and specialty medicines. The company is listed on the Nasdaq Global Select Market under the ticker GILD and reported total assets of $59,023 million as of December 31, 2025. On February 22, 2026, Gilead entered into a definitive merger agreement to acquire Arcellx, Inc. through a cash tender offer.

What is GILD's DredgeCap risk score?

DredgeCap's AI analysis rates GILD at 3.2/10 on the risk scale — Low risk. This score reflects dilution exposure, debt toxicity, liquidity position, and going-concern posture as disclosed in SEC filings.

Does GILD have a going concern warning?

No current auditor going-concern warning is flagged in GILD's SEC filings. Risk assessment is based on other filing-disclosed factors.

When did GILD last file with the SEC?

GILD's most recent SEC filing was a 10-K filed 2026-02-24. All filings are available on SEC EDGAR.

← GILD Overview

8-KMay 7, 2026

GILD — 8-K Filing

Track GILD for Alerts

8-K Items Disclosed

Item 2.02 — Results of Operations and Financial Condition

Quarterly or annual earnings results released. Often paired with a press release as Exhibit 99.1.

Item 9.01 — Financial Statements and Exhibits

Press releases, exhibits, and supporting documents attached to this filing.

GILD Filing Excerpt

gild-20260507UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 FORM 8-K CURRENT REPORTPursuant to Section 13 or 15(d) ofThe Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): May 7, 2026 GILEAD SCIENCES, INC.(Exact name of registrant as specified in its charter) Delaware000-1973194-3047598(State or Other Jurisdiction of Incorporation)(Commission File No.)(IRS Employer Identification No.)333 Lakeside Drive, Foster City, California (Address of principal executive offices)94404 (Zip Code)650-574-3000 (Registrant’s Telephone Number, Including Area Code)Not Applicable(Former name or former address, if changed since last report)Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the…

Current DredgeCap Risk Profile

Risk Score

3.2/10

MODERATE

Dilution

1.8

Debt Toxicity

3.5

Going Concern

✓ Not flagged

The risk profile above reflects the latest cached DredgeCap analysis for GILD. For the full filing-by-filing analyst report (red flags, primary risk driver, what moves the stock), open GILD's company page.

What is a 8-K?

A current report disclosing a material event that occurred between regular reporting periods. Companies are required to file an 8-K within four business days of certain events including earnings releases, executive changes, acquisitions, debt obligations, restructurings, and material agreements. Each 8-K specifies one or more 'Items' identifying which event triggered the filing.

More on GILD

The plain-language summary above is composed mechanically from the filing's reported numbers — no analysis or opinion. Form-type explainers and 8-K item descriptions are derived from SEC documentation. This page does not constitute investment advice. Always consult the original filing on SEC EDGAR for authoritative content, and consult a licensed financial advisor for investment decisions.